Reserpine

Hypertensive disease

Treatment

1 FDA approval

20 Active Studies for Reserpine

What is Reserpine

Reserpine

The Generic name of this drug

Treatment Summary

Reserpine is a type of alkaloid found in two plants, Rauwolfia serpentina and R. vomitoria. It works by blocking the uptake of norepinephrine into storage vesicles, which leads to a decrease of catecholamines and serotonin in the body. It has been used to treat high blood pressure and certain mental health conditions, but its side effects limit its use in clinical settings.

Ser-Ap-Es

is the brand name

image of different drug pills on a surface

Reserpine Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Ser-Ap-Es

Reserpine

1960

8

Approved as Treatment by the FDA

Reserpine, also called Ser-Ap-Es, is approved by the FDA for 1 uses like Hypertensive disease .

Hypertensive disease

Used to treat High Blood Pressure (Hypertension) in combination with Polythiazide

Effectiveness

How Reserpine Affects Patients

Reserpine is a drug used to lower blood pressure by blocking substances (norepinephrine) that control the rate of your heart, the force of your heart's contractions, and the amount of resistance in your blood vessels. It does this by preventing these substances from being stored in nerve endings.

How Reserpine works in the body

Reserpine stops the body from storing neurotransmitters in presynaptic neurons. This prevents the neurotransmitters from being available to be used, and they are instead broken down by an enzyme called monoamine oxidase. This reduces the amount of catecholamines in the body.

When to interrupt dosage

The suggested quantity of Reserpine is contingent upon the diagnosed condition. The dosage fluctuates as per the delivery method outlined in the table beneath.

Condition

Dosage

Administration

Hypertensive disease

, 0.1 mg, 0.25 mg, 0.125 mg, 25.0 mg

Oral, Tablet, , Tablet - Oral, Tablet, coated, Tablet, coated - Oral

Warnings

There are 20 known major drug interactions with Reserpine.

Common Reserpine Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The serum concentration of Abemaciclib can be increased when it is combined with Reserpine.

Amifostine

Major

Reserpine may increase the hypotensive activities of Amifostine.

Amisulpride

Major

Reserpine may increase the antipsychotic activities of Amisulpride.

Astemizole

Major

The metabolism of Astemizole can be increased when combined with Reserpine.

Axitinib

Major

The serum concentration of Axitinib can be increased when it is combined with Reserpine.

Reserpine Toxicity & Overdose Risk

This drug has the potential to cause cancer in humans. It may also harm reproductive health. Tests have shown that when given orally to rats, the lethal dose is 420mg/kg, when given intravenously it is 15mg/kg, and when given to mice, it is 200mg/kg and 52mg/kg respectively. When given by injection to rabbits, the lethal dose is 7mg/kg.

image of a doctor in a lab doing drug, clinical research

Reserpine Novel Uses: Which Conditions Have a Clinical Trial Featuring Reserpine?

18 active trials are currently underway to assess the utility of Reserpine for the treatment of Hypertensive disease.

Condition

Clinical Trials

Trial Phases

Hypertensive disease

30 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3

Reserpine Reviews: What are patients saying about Reserpine?

5

Patient Review

3/10/2012

Reserpine for High Blood Pressure

I've been using this medication for 30 years now and it's still working great with no side effects!

5

Patient Review

6/9/2010

Reserpine for Severe Mental Disorder with Loss of Personality & Reality

This treatment is amazing. I'm grateful for modern medicine.

4.3

Patient Review

6/25/2009

Reserpine for High Blood Pressure

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about reserpine

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the drug reserpine used for?

"Reserpine is a medication used to lower blood pressure, treat psychiatric disorders, and tardive dyskinesia. It is available as the brand name Serpasil."

Answered by AI

Why reserpine is not used clinically?

"Reserpine was approved for use in the United States in 1955. However, it is currently not often used because it can cause central nervous system effects and there are many other antihypertensive medications that are more tolerated and more potent."

Answered by AI

What is reserpine mechanism of action?

"Reserpine irreversibly blocks the vesicular monoamine transporter-2 (VMAT-2), which is involved in adrenergic neurotransmission. This blockage prevents serotonin, norepinephrine, and dopamine from being taken up into presynaptic storage vesicles."

Answered by AI

Where is reserpine found?

"In the 1950s the Indian scientist K.C. Appa and his colleagues showed that reserpine, the principal alkaloid of the root, was the active ingredient in treating high blood pressure

Reserpine is a drug that comes from the roots of certain tropical plants in the Rauwolfia species. In the past, the powdered root of the Indian shrub Rauwolfia serpentina was used to treat snakebites, insomnia, and high blood pressure. In the 1950s, Indian scientist K.C. Appa and his colleagues discovered that reserpine, the main alkaloid in the root, was what was actually effective in treating high blood pressure."

Answered by AI

Clinical Trials for Reserpine

Image of University of California, San Diego in San Diego, United States.

BPCARE Intervention for High Blood Pressure

18+
All Sexes
San Diego, CA

The goal of this randomized clinical trial is to determine whether a community health worker-delivered, multi-component behavioral intervention can improve antihypertensive medication adherence and blood pressure control among adult refugees with hypertension who are prescribed antihypertensive medications. The main questions it aims to answer are: 1. Does participation in the BPCARE intervention improve antihypertensive medication adherence compared to enhanced usual care? 2. Does participation in the BPCARE intervention improve blood pressure control and persistence over time compared to enhanced usual care? Researchers will compare participants randomized to the BPCARE intervention to those receiving enhanced usual care (hypertension information and a home blood pressure monitor) to determine the effects on medication adherence, blood pressure control, and persistence. Participants will: * Be randomly assigned to either the BPCARE intervention or enhanced usual care * Receive hypertension education and a home blood pressure monitor * Participate in community health worker-delivered sessions that include hypertension and medication education, motivational interviewing, problem-solving, and action planning (intervention arm only) * Complete questionnaires assessing medication adherence and related psychosocial factors * Have blood pressure monitored using connected home blood pressure devices * Complete pill counts to assess medication adherence over a nine-month follow-up period

Recruiting
Has No Placebo

University of California, San Diego (+1 Sites)

Image of National Association of Pasifika Organizations in Fayetteville, United States.

PILI Pasifika Program for Cardiometabolic Conditions

18+
All Sexes
Fayetteville, AR

In this study, the investigators are testing the effectiveness and implementation of the Community Health Workers (CHW)-delivered PILI Pasifika Program (PPP) Standard Facilitation or Enhanced Facilitation across 3 regions, the U.S. Affiliated Pacific Islands (USAPI), the continental U.S., and Hawai'i, among 600 Native Hawaiian and Pacific Islander (NHPI) participants in two settings, (clinical and non-clinical) over a 3-year period. The PPP is a 3-month lifestyle intervention that includes a Social Determinants of Health (SDOH) component and was NHPI-adapted from the Diabetes Prevention Program's Lifestyle Program, renamed to the PILI Lifestyle Program (PLP), which demonstrated effectiveness in improving weight, blood pressure, physical activity, and diet among NHPIs. The PPP consists of 8 lifestyle lessons and 4 SDOH activities delivered over a 3-month period. The investigators will conduct an effectiveness-implementation hybrid type 2 trial using a 3 (Region) x 2 (Setting) x 2 (Delivery Mode) factorial design. The long-term objective of this study is threefold: 1. To conduct an effectiveness-implementation hybrid 2 trial to test the effects of the PPP implementation strategies across different settings and modes of delivery among 600 NHPIs at risk for cardiometabolic-related conditions using an NHPI-approved and adapted evaluation framework. The investigators will also assess and compare the cost-effectiveness of the CHW-delivered PPP-Standard Facilitation and PPP-Enhanced Facilitation to support long-term sustainability. 2. To conduct a longitudinal Social Determinants of Health (SDOH) survey embedded within the trial to examine the reliability and validity of indices from 5 adapted SDOH instruments and to assess the associations between SDOH variables and chronic disease risk among NHPIs. 3. To implement and evaluate the contextually-based CHW training program on PPP delivery.

Waitlist Available
Has No Placebo

National Association of Pasifika Organizations (+1 Sites)

Joseph K Kaholokula, PhD

Image of Rush University Medical Center in Chicago, United States.

Food is Medicine for High Blood Pressure

18+
All Sexes
Chicago, IL

The goal of this clinical trial is to assess nutrition incentives and produce vouchers to measure the impacts of food insecurity-related chronic health conditions in adults with hypertension and/or diabetes. The main questions it aims to answer are: * Does participation increase fruit and vegetable consumption for participants? * Does participation reduce individual and household food insecurity? * Does participation reduce healthcare utilization and associated costs? * Does participation lead to improvements in diet-related health outcomes (e.g., hypertension, diabetes)? * Does participation support the local economy by increasing participant spending at local food vendors? Participants will: * Receive 6 months home delivered produce prescription boxes * Receive 6 months match of produce vouchers * Receive nutrition education and participate in Chronic Disease Self-Management classes

Waitlist Available
Has No Placebo

Rush University Medical Center

Traci Simmons, DrPHc, MPH

Image of Miles Square Health Center Chicago in Chicago, United States.

Food is Medicine for High Blood Pressure and Obesity

Any Age
All Sexes
Chicago, IL

The goal of this clinical trial is to treat both hypertension and obesity in adults using a food is medicine framework. Participants will be randomized 1:1 to FIM+DASH or usual-care control. The 24-week trial includes a 12-week FIM+DASH intervention followed by a 12-week maintenance period and leverages existing partnerships with community-based organizations for home food delivery and culinary skill-skill building. The main questions it aims to answer are: (1) What is the effect of FIM+DASH vs. usual care control on blood pressure? (2) What is the effect of FIM+DASH vs. usual care control on DASH diet adherence (diet quality), body weight, and waist circumference? (3) How to identify factors associated with the sustainability and scalability of FIM+DASH in real-world settings?

Phase 2
Waitlist Available

Miles Square Health Center Chicago (+3 Sites)

Have you considered Reserpine clinical trials?

We made a collection of clinical trials featuring Reserpine, we think they might fit your search criteria.
Go to Trials
Image of University of Alabama at Birmingham in Birmingham, United States.

Dietary Interventions for Hypertension

18+
All Sexes
Birmingham, AL

Natriuretic peptides (NPs) are hormones produced by the heart and play an important role in maintaining cardiovascular health and have favorable metabolic benefits. Low NP levels are associated with an increased likelihood of the development of cardiometabolic diseases like diabetes and hypertension. NP levels are known to be highly heritable, with up to half of the differences in NP levels being explained by genetics. The investigators aim to describe the genetic architecture of NPs by examining the genetic variants associated with NPs, and generate and validate a polygenic score (PGS) for NPs. The investigators will use this NP PGS to examine the association of genetically determined NP levels with cardiometabolic and cardiovascular outcomes. The investigators will conduct a genotype-guided physiological clinical trial that aims to assess the genetic factors affecting NP levels and their impact on blood pressure and NP response to saline infusion, high-salt diet, and low-salt diet. These findings will help support personal medicine approaches to lower the increasing burden of hypertension in the United States.

Waitlist Available
Has No Placebo

University of Alabama at Birmingham

Pankaj Arora, MD, FAHA

Have you considered Reserpine clinical trials?

We made a collection of clinical trials featuring Reserpine, we think they might fit your search criteria.
Go to Trials
Image of Wayne Health Mobile Units in Detroit, United States.

Text Message Reminders for High Blood Pressure

18+
All Sexes
Detroit, MI

This project is part of the ACHIEVE GREATER (Addressing Cardiometabolic Health In Populations Through Early PreVEntion in the GREAT LakEs Region) Center (IRB# 100221MP2A), the purpose of which is to improve cardiometabolic health in two uniquely comparable cities: Detroit, Michigan, and Cleveland, Ohio. The ACHIEVE GREATER Center involves separate but related projects that aim to improve cardiometabolic health outcomes through better risk factor control for three chronic conditions that are of tremendous public health importance, (hypertension (HTN), heart failure, and coronary heart disease), all of which contribute significantly to premature death in Detroit and Cleveland. The present study is the prospective observational cohort component of ACHIEVE P1- EPI (Project 1) of the ACHIEVE GREATER Center and serves to characterize the population of patients with blood pressure (BP) levels above normal attending The Wayne Health Mobile Health Unit (MHU) events to better understand key factors (e.g., social determinants of health) that convey information about baseline BP levels and related clinical outcomes (e.g., follow-up clinic visits, BP control, and cardiovascular events).

Recruiting
Has No Placebo

Wayne Health Mobile Units

Steven J Korzeniewski, PhD

Image of University of Alberta in Edmonton, Canada.

Egg White Powder for High Blood Sugar and High Blood Pressure

18 - 70
All Sexes
Edmonton, Canada

Bioactive peptides derived from food proteins show potential for improving human health. One of such promising peptides is namely IRW made from egg white hydrolysate and composed of three peptides. This is a feasibility study to assess the acute effect of IRW in egg white hydrolysate for the management of high sugar and blood pressure. Participants at high risk of type 2 diabetes (T2D) or having T2D will undergo 4 consecutive treatments of 1 day each (randomly), during which they will consume a standardized breakfast with a smoothie containing different protein powders. Each treatment will be separated by a minimum of 1-week. Participants in the healthy control group will undergo 1 treatment only (one day).

Phase 1
Recruiting

University of Alberta

Jianping Wu, PhD

Image of Northern Arizona University in Flagstaff, United States.

CardioCare Quest for High Blood Pressure

18+
All Sexes
Flagstaff, AZ

This project aims to address healthcare disparities among Navaho people diagnosed with hypertension or prehypertension through three main objectives. Firstly, it identifies and shares insights on healthcare access disparities affecting Navaho individuals experiencing nonadherence to hypertension treatment. Secondly, the proposal develops a telehealth solution based on factors identified as knowledge gaps caused by healthcare access disparities in hypertension management; we will use the factors to design a series of engaging minigames that can be incorporated into the larger CardioCare Quest. These minigames will be co-designed with end users and clinicians. Finally, the proposal conducts comprehensive qualitative and quantitative assessments of user experiences, perceptions, and challenges with CardioCare Quest.

Recruiting
Has No Placebo

Northern Arizona University (+1 Sites)

Tochukwu Ikwunne, PhD

Have you considered Reserpine clinical trials?

We made a collection of clinical trials featuring Reserpine, we think they might fit your search criteria.
Go to Trials